PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.33%
Revenue growth under 50% of MCHP's 9.54%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-1.92%
Negative gross profit growth while MCHP is at 10.30%. Joel Greenblatt would examine cost competitiveness or demand decline.
-542.50%
Negative EBIT growth while MCHP is at 7.73%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-231.58%
Negative operating income growth while MCHP is at 7.73%. Joel Greenblatt would press for urgent turnaround measures.
-293.42%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-274.42%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-274.42%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.10%
Slight or no buybacks while MCHP is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-2.51%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
2.32%
Dividend growth of 2.32% while MCHP is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-7.27%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-52.53%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
53.71%
10Y revenue/share CAGR under 50% of MCHP's 107.71%. Michael Burry would suspect a lasting competitive disadvantage.
11.08%
5Y revenue/share CAGR under 50% of MCHP's 107.71%. Michael Burry would suspect a significant competitive gap or product weakness.
3.47%
3Y revenue/share CAGR under 50% of MCHP's 107.71%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
12095.78%
5Y OCF/share CAGR above 1.5x MCHP's 24.53%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-44.04%
Negative 3Y OCF/share CAGR while MCHP stands at 24.53%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-937.41%
Negative 10Y net income/share CAGR while MCHP is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1.99%
Negative 5Y net income/share CAGR while MCHP is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-193.53%
Negative 3Y CAGR while MCHP is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
50.55%
Below 50% of MCHP's 150.06%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
66.64%
Below 50% of MCHP's 150.06%. Michael Burry suspects a serious short-term disadvantage in building book value.
108.73%
Dividend/share CAGR of 108.73% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-69.20%
Negative 5Y dividend/share CAGR while MCHP stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
33.29%
3Y dividend/share CAGR of 33.29% while MCHP is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
10.02%
AR growth well above MCHP's 14.72%. Michael Burry fears inflated revenue or higher default risk in the near future.
-13.16%
Inventory is declining while MCHP stands at 9.68%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.42%
Asset growth well under 50% of MCHP's 12.08%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-3.93%
We have a declining book value while MCHP shows 14.21%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
44.26%
Debt growth far above MCHP's 58.10%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
90.64%
R&D growth drastically higher vs. MCHP's 11.94%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-2.24%
We cut SG&A while MCHP invests at 9.84%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.